These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19729101)

  • 1. Tachyphylaxis and bevacizumab.
    Avgikos KN; Horgan SE; Sivaraj RR; Hu K
    Ophthalmology; 2009 Sep; 116(9):1831-2; author reply 1832. PubMed ID: 19729101
    [No Abstract]   [Full Text] [Related]  

  • 2. Tachyphylaxis and bevacizumab.
    Ziemssen F; Neuhann IM; Voelker M
    Ophthalmology; 2009 Aug; 116(8):1591-2; author reply 1592-3. PubMed ID: 19651319
    [No Abstract]   [Full Text] [Related]  

  • 3. Bevacizumab tachyphylaxis.
    Falavarjani KG; Modarres M
    Ophthalmology; 2009 May; 116(5):1016-7; author reply 1017. PubMed ID: 19410964
    [No Abstract]   [Full Text] [Related]  

  • 4. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?
    Schaal S; Kaplan HJ; Tezel TH
    Ophthalmology; 2008 Dec; 115(12):2199-205. PubMed ID: 18930553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration.
    Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F
    Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microperimetric changes after intravitreal bevacizumab for exudative age-related macular degeneration.
    Rensch F; Jonas JB
    Acta Ophthalmol; 2008 Sep; 86(6):696-7. PubMed ID: 18752522
    [No Abstract]   [Full Text] [Related]  

  • 7. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.
    Aggio FB; Melo GB; Höfling-Lima AL; Eid Farah M
    Acta Ophthalmol Scand; 2006 Dec; 84(6):831-3. PubMed ID: 17083553
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Kumar V; Ghosh B; Raina UK; Goel N
    Am J Ophthalmol; 2008 Dec; 146(6):974; author reply 974-5. PubMed ID: 19027427
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravitreal bevacizumab and triamcinolone acetonide combination therapy for exudative neovascular age-related macular degeneration: short-term optical coherence tomography results.
    Colucciello M
    J Ocul Pharmacol Ther; 2008 Feb; 24(1):15-24. PubMed ID: 18201136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
    Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
    Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined intravitreal bevacizumab and triamcinolone acetonide injection for idiopathic neuroretinitis.
    Cakir M; Cekiç O; Bozkurt E; Pekel G; Yazici AT; Yilmaz OF
    Ocul Immunol Inflamm; 2009; 17(3):221-3. PubMed ID: 19585368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration.
    Forooghian F; Cukras C; Meyerle CB; Chew EY; Wong WT
    Retina; 2009 Jun; 29(6):723-31. PubMed ID: 19516114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
    Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
    Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Juxtapapillary capillary hemangioma treated by intravitreal injection of bevacizumab combined with posterior subtenon injection of triamcinolone acetonide.
    Toyokawa N; Kimura H; Kuroda S
    Jpn J Ophthalmol; 2010 Mar; 54(2):168-70. PubMed ID: 20401570
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
    Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
    Retina; 2006; 26(9):994-8. PubMed ID: 17151485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing ranibizumab with bevacizumab.
    Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
    Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
    Bom Aggio F; Eid Farah M; Melo GB
    Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.